BioSpace News Archive

How the first hours, days and weeks of a potential terror or biological attack or the rise of a new infectious disease are managed, has a huge impact on the outcome.

AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or no treatment options, today announced that its management will present a corporate overview at the Cowen and Company 40 th Annual Health Care Conference at 12 p.m. ET on Tuesday, March 3,

Dr. Dennis Gross, a New York City board-certified dermatologist with a background in skin cancer research, released a statement citing concerns after a new study published by the Food and Drug Administration (FDA) showed six common chemical sunscreen ingredients absorb into the bloodstream and greatly exceed levels considered safe

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in Raymond James & Associates’ 41 st Annual Institutional Investors Conference at the JW Marriott Grande Lakes in Orlando.

Program for physician-scientists to progress promising discoveries toward clinical trials

Horizon Therapeutics (Nasdaq: HZNP) and Willis Towers Watson (Nasdaq: WLTW) are partnering with Willis Tower to light the antennas of the Willis Tower on Feb. 29 in recognition of Rare Disease Day and to raise awareness of the crucial need to identify new medicines for the 30 million people living with rare diseases in the United States

Awards recognize the rise of purpose in business and build on Loyola’s role as global leader in social business education. Loyola’s Baumhart Center for Social Enterprise and Responsibility today announced the awardees of its inaugural Innovator in Social Business Awards . The awards are presented to extraordinary companies committed to doing well and doing good across three categories: Social Impact, Environmental

Cepheid and Sherlock Biosciences today announced a research collaboration between the two companies to explore the development of new cutting-edge molecular diagnostic tests. Leveraging Sherlock Biosciences’ engineering biology platform, SHERLOCK™, a CRISPR-based technology that can identify virtually any genetic target, new tests could be designed to run on Cepheid’s GeneXpert® Systems.

Encompass Health Corp. announced it has purchased land near the 4900 block of 12th Ave. in Pensacola, Florida with plans to build a 40-bed inpatient rehabilitation hospital to serve patients recovering from debilitating illnesses and injuries.

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights.